Baidu
map

Nature:siRNA干预治疗埃博拉病毒感染新进展

2015-04-24 MedSci 生物谷

埃博拉病毒在西非地区的流行仍未得到有效控制,其造成的病例和死亡比之前的病毒爆发流行都要严重,是一次前所未有的大灾难。近日,著名国际学术期刊nature在线发表了美国科学家关于埃博拉病毒治疗进展的相关研究。   在此研究之前,科学家们已经研发出一些病毒接触后干预手段,对返回欧洲和美国的病人进行治疗。但这些治疗手段对于治疗埃博拉病毒新暴发亚型的体内疗效仍未可知。   在该项

埃博拉病毒在西非地区的流行仍未得到有效控制,其造成的病例和死亡比之前的病毒爆发流行都要严重,是一次前所未有的大灾难。近日,著名国际学术期刊nature在线发表了美国科学家关于埃博拉病毒治疗进展的相关研究。
 
在此研究之前,科学家们已经研发出一些病毒接触后干预手段,对返回欧洲和美国的病人进行治疗。但这些治疗手段对于治疗埃博拉病毒新暴发亚型的体内疗效仍未可知。
 
在该项研究中,研究人员发现针对马科纳河爆发的埃博拉病毒亚型开发出的脂质纳米颗粒包裹的siRNA能够完全保护恒河猴面对埃博拉病毒的致命挑战,他们在恒河猴接触埃博拉病毒3天,出现病毒血症和临床疾病症状后,开始对其进行siRNA干预治疗,治疗结果非常好。在该实验中,所有感染动物都表现出病毒感染晚期症状,包括血液学和血生化异常,凝血功能障碍,但进行了siRNA治疗的动物其临床特征得到改善,最终完全恢复,而未进行治疗的对照动物最终都死于埃博拉病毒感染。
 
这项研究中,研究人员成功地在非人灵长类动物上证明了一些对抗新埃博拉病毒的治疗方法的有效性,并着重强调了脂质纳米颗粒携带siRNA治疗埃博拉病毒感染的重要作用,该种方法或可对埃博拉病毒感染治疗,控制西非埃博拉病毒流行趋势具有重要意义。

原始出处:

Emily P.Thi,Chad E. Mire,Amy C.H.Lee,Joan B. Geisbert,Joy Z.Zhou,Krystle N. Agans, Nicholas M. Snead,Daniel J. Deer,Trisha R.Barnard,Karla A.Fenton,Ian MacLachlan& Thomas W.Geisbert.Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates. Nature, April 22, 2015; doi:10.1038/nature14442

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1650333, encodeId=00011650333db, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Sat Oct 10 17:13:00 CST 2015, time=2015-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880611, encodeId=75d2188061108, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Aug 17 03:13:00 CST 2015, time=2015-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23487, encodeId=f82c2348e89, content=看看!, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5571624672, createdName=Wuyue6233, createdTime=Wed May 13 22:19:00 CST 2015, time=2015-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296440, encodeId=8139129644028, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Sun Apr 26 00:13:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548187, encodeId=a854154818eb2, content=<a href='/topic/show?id=c87e16332da' target=_blank style='color:#2F92EE;'>#siRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16332, encryptionId=c87e16332da, topicName=siRNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271114029857, createdName=12498ebem23暂无昵称, createdTime=Sun Apr 26 00:13:00 CST 2015, time=2015-04-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1650333, encodeId=00011650333db, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Sat Oct 10 17:13:00 CST 2015, time=2015-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880611, encodeId=75d2188061108, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Aug 17 03:13:00 CST 2015, time=2015-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23487, encodeId=f82c2348e89, content=看看!, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5571624672, createdName=Wuyue6233, createdTime=Wed May 13 22:19:00 CST 2015, time=2015-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296440, encodeId=8139129644028, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Sun Apr 26 00:13:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548187, encodeId=a854154818eb2, content=<a href='/topic/show?id=c87e16332da' target=_blank style='color:#2F92EE;'>#siRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16332, encryptionId=c87e16332da, topicName=siRNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271114029857, createdName=12498ebem23暂无昵称, createdTime=Sun Apr 26 00:13:00 CST 2015, time=2015-04-26, status=1, ipAttribution=)]
    2015-08-17 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1650333, encodeId=00011650333db, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Sat Oct 10 17:13:00 CST 2015, time=2015-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880611, encodeId=75d2188061108, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Aug 17 03:13:00 CST 2015, time=2015-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23487, encodeId=f82c2348e89, content=看看!, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5571624672, createdName=Wuyue6233, createdTime=Wed May 13 22:19:00 CST 2015, time=2015-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296440, encodeId=8139129644028, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Sun Apr 26 00:13:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548187, encodeId=a854154818eb2, content=<a href='/topic/show?id=c87e16332da' target=_blank style='color:#2F92EE;'>#siRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16332, encryptionId=c87e16332da, topicName=siRNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271114029857, createdName=12498ebem23暂无昵称, createdTime=Sun Apr 26 00:13:00 CST 2015, time=2015-04-26, status=1, ipAttribution=)]
    2015-05-13 Wuyue6233

    看看!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1650333, encodeId=00011650333db, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Sat Oct 10 17:13:00 CST 2015, time=2015-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880611, encodeId=75d2188061108, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Aug 17 03:13:00 CST 2015, time=2015-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23487, encodeId=f82c2348e89, content=看看!, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5571624672, createdName=Wuyue6233, createdTime=Wed May 13 22:19:00 CST 2015, time=2015-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296440, encodeId=8139129644028, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Sun Apr 26 00:13:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548187, encodeId=a854154818eb2, content=<a href='/topic/show?id=c87e16332da' target=_blank style='color:#2F92EE;'>#siRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16332, encryptionId=c87e16332da, topicName=siRNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271114029857, createdName=12498ebem23暂无昵称, createdTime=Sun Apr 26 00:13:00 CST 2015, time=2015-04-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1650333, encodeId=00011650333db, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Sat Oct 10 17:13:00 CST 2015, time=2015-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880611, encodeId=75d2188061108, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Aug 17 03:13:00 CST 2015, time=2015-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23487, encodeId=f82c2348e89, content=看看!, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5571624672, createdName=Wuyue6233, createdTime=Wed May 13 22:19:00 CST 2015, time=2015-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296440, encodeId=8139129644028, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Sun Apr 26 00:13:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548187, encodeId=a854154818eb2, content=<a href='/topic/show?id=c87e16332da' target=_blank style='color:#2F92EE;'>#siRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16332, encryptionId=c87e16332da, topicName=siRNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271114029857, createdName=12498ebem23暂无昵称, createdTime=Sun Apr 26 00:13:00 CST 2015, time=2015-04-26, status=1, ipAttribution=)]

相关资讯

Nat Med: CKIP-1基因小核酸干扰治疗能逆转骨质疏松

最近,军事医学科学院的一项动物实验证实,一种能够特异性携带任何具有成骨潜能的小核酸到达骨形成部位的靶向递送系统,能够高效而安全地促进携带的成骨小核酸逆转骨质疏松,为骨质疏松治疗的应用基础研究与核酸药物研发提供了坚实基础。   1月30日,最新出版的国际著名学术期刊《自然-医学》杂志在线发表了香港中文大学矫形外科及创伤学系张戈教授团队、军事医学科学院蛋白质组学国家重点实验室张令强研究员团队、中国

JCI:siRNA筛选发现促乳腺癌转移关键因子

近日,著名国际期刊JCI在线发表了荷兰莱顿大学研究人员的一项最新研究成果,他们利用小干扰RNA对H1299细胞内与细胞迁移有关的基因进行了筛选,发现了一些与肿瘤细胞迁移速度和持续性有关的基因,并发现了与乳腺癌病人肿瘤转移密切相关的SRPK1基因或可成为乳腺癌药物治疗的潜在靶点,因此具有重要意义。   肿瘤细胞迁移是癌细胞扩散的一个重要过程,而这一过程主要通过信号介导的细胞骨架和细

Baidu
map
Baidu
map
Baidu
map